Business Context and Reporting Period
Company: Materialise NV
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter and Full Year ended December 31, 2024
Filing Date: February 20, 2025
Business Overview: Materialise provides 3D printing software solutions and services across healthcare, automotive, aerospace, and consumer goods sectors. The company operates through three segments: Materialise Medical, Materialise Software, and Materialise Manufacturing.
Key Financial Metrics
Full Year 2024 Performance
- Total Revenue: 266,765 kEUR (up 4.2% vs. 2023).
- Gross Profit: 150,826 kEUR (margin 56.5% vs. 56.7% in 2023).
- Net Profit: 13,406 kEUR (up from 6,695 kEUR in 2023).
- Operating Profit: 9,432 kEUR (up from 5,619 kEUR in 2023).
- Adjusted EBITDA: 31,484 kEUR (margin 11.8% vs. 12.3% in 2023).
- Operating Cash Flow: 31,456 kEUR (up from 20,157 kEUR in 2023).
- Cash and Equivalents: 102,304 kEUR (down from 127,573 kEUR at year-end 2023).
- Gross Debt: 41,284 kEUR (down from 64,398 kEUR at year-end 2023).
Fourth Quarter 2024 Performance
- Total Revenue: 65,680 kEUR (up 0.6% vs. Q4 2023).
- Gross Profit: 36,365 kEUR (margin 55.4% vs. 57.5% in Q4 2023).
- Net Profit: 2,907 kEUR (vs. net loss of 539 kEUR in Q4 2023).
- Operating Result: (1,268) kEUR loss (vs. (1,113) kEUR loss in Q4 2023).
- Adjusted EBITDA: 4,306 kEUR (down from 8,474 kEUR in Q4 2023).
- Operating Cash Flow: 6,218 kEUR (up from 195 kEUR in Q4 2023).
Material Changes vs. Prior Period
- Segment Revenue Divergence: Materialise Medical revenue grew 14.8% for the full year (116,358 kEUR), while Materialise Software declined 1.2% and Materialise Manufacturing declined 3.4%.
- Profitability Drivers: The significant increase in full-year net profit was driven by the absence of non-recurring impairment charges (4,228 kEUR) recorded in 2023 and favorable net financial results (4,707 kEUR vs. 1,154 kEUR in 2023) due to exchange rate fluctuations.
- Expense Growth: R&D, Sales & Marketing, and G&A expenses increased 10.2% in Q4 2024, primarily due to a 19.6% rise in R&D spend.
- Manufacturing Segment Strain: The Materialise Manufacturing segment reported negative Adjusted EBITDA of (2,989) kEUR in Q4 2024, a sharp decline from positive 557 kEUR in Q4 2023.
- Balance Sheet: Gross debt was reduced by approximately 23 million EUR year-over-year, while cash reserves decreased by roughly 25 million EUR, largely due to capital expenditures of 26,377 kEUR for the year.
Outlook, Risks, and Unusual Items
- Unusual Items: The 2023 comparative period included significant non-recurring impairment charges of 4,228 kEUR related to goodwill and assets of Materialise Motion and Engimplan. These were absent in 2024.
- Non-IFRS Measures: Management utilizes Adjusted EBITDA and Adjusted EBIT to evaluate performance, excluding share-based compensation, acquisition-related expenses, and impairments. The filing notes these measures do not reflect cash requirements for debt service or periodic costs of capitalized assets.
- Capital Expenditures: Significant investment activity continued with total capital expenditures of 26,377 kEUR for 2024, including 24,649 kEUR for property, plant, and equipment.
- Exchange Rate Impact: Financial results were positively impacted by favorable exchange rate fluctuations in the fourth quarter.
Investor Verification Checklist
- Verify the sustainability of the Materialise Medical segment's growth (14.8% YoY) versus the contraction in the Manufacturing segment.
- Assess the impact of the 19.6% increase in R&D spending on future product pipelines and profitability.
- Review the negative Adjusted EBITDA in the Manufacturing segment for Q4 2024 to understand operational headwinds.
- Monitor the reduction in cash reserves (from 127.6M to 102.3M EUR) against the high level of capital expenditures.
- Confirm the extent to which the 2024 net profit improvement is driven by the absence of 2023 impairments versus organic operational improvement.